Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160494 · ClinicalTrials.gov registry record · Phase 1
D2C7-IT With Atezolizumab for Recurrent Gliomas
A Phase 1 study of Malignant Glioma, sponsored by Darell Bigner.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04160494 is a Phase 1 study of Malignant Glioma that is active but no longer recruiting, run by Darell Bigner. The registered enrollment target is 18 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04160494, a Phase 1 study of Malignant Glioma, is active but no longer recruiting, sponsored by Darell Bigner.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Conditions Studied
Interventions
- DRUG D2C7-IT (6920 ng/mL via convection-enhanced delivery)
- DRUG Atezolizumab (1200 mg every three weeks)
- DRUG D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04160494
The ClinicalTrials.gov registry entry for NCT04160494 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower). The listed sponsor is Darell Bigner, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 3 interventions - of which D2C7-IT (6920 ng/mL via convection-enhanced delivery) is the first listed.
NCT04160494 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04160494 about?
NCT04160494 is a clinical study titled "D2C7-IT With Atezolizumab for Recurrent Gliomas". This is a phase 1 study of atezolizumab in combination with D2C7-IT, a dual-specific monoclonal antibody (mAB) with a high affinity for both EGFRwt- and EGFRvIII-expressing cells, in patients with recurrent World Health Organization (WHO) grade IV malignant glioma at the Preston Robert Tisch Brain T...
What is the current status of trial NCT04160494?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-02-25. Estimated completion is 2027-12.
What conditions does trial NCT04160494 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT04160494?
The interventions under investigation include: D2C7-IT (6920 ng/mL via convection-enhanced delivery) (DRUG), Atezolizumab (1200 mg every three weeks) (DRUG), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery) (DRUG).
Who is sponsoring clinical trial NCT04160494?
This trial is sponsored by Darell Bigner, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160494 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.